NCT04497792View on ClinicalTrials.gov

Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2019

Conditions

Coronary Artery DiseaseDiabetes MellitusPercutaneous Coronary Intervention

Interventions

DRUG

Empagliflozin 10Mg Tab

Patients from treatment group received empagliflozin 10 mg daily additionally to previously prescribed diabetes medication

DRUG

hypoglycemic therapy

hypoglycemic therapy.

All Listed Sponsors

lead

Research Institute for Complex Problems of Cardiovascular Diseases, Russia

OTHER

NCT04497792 - Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions | Biotech Hunter | Biotech Hunter